Faguet G. B. A brief history of cancer: Age — old milestones underlying our current knowledge database // International Journal of Cancer, 2015, May 5; 136 (9), 2022–2036.

Online Summary of Trends in US Cancer Control Measures https://progressreport.cancer.gov/after/survival.

Pinquart M. & Duberstein P. R. Depression and cancer mortality: a meta-analysis // Psychological Medicine, 2010, 40 (11), 1797–1810.

Satin J. R, Linden W., Phillips M. J. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis // Cancer, 2009, 115 (22), 5349–5361.

Siegel R. L., Kimberly D. M., Ahmedin J. Cancer statistics, 2017 // A Cancer Journal for Clinicians, 2017, 67, 7–30.

Skuse A. Wombs, Worms and Wolves: Constructing Cancer in Early Modern England // Social History of Medicine, 27 (4), 632–648.

Umar A., Dunn B. K., Greenwald P. Future directions in cancer prevention // Nature Reviews Cancer, 2012, 12, 835–848.

Глава 2. Загадки нашего генома и мифы о природе рака

Горбань А., Хлебопрос Р. Демон Дарвина. Идея оптимальности и естественный отбор. — М.: Наука, 1988.

Киселев Л. Л., Абелев Г. И., Киселев Ф. Л. Лев Зильбер — создатель отечественной школы медицинских вирусологов // Вестник российской академии наук. 2003. Т. 73. № 7. С. 647–659.

Киселев Ф. Л., Боринская С. А. Вакцина против рака — первые успехи // Природа. 2007. № 3.

Киселев Ф. Л., Имянитов Е. Н., Киселева Н. П., Левина Е. С. Молекулярная онкология: от вирусной теории к лечению рака. — М.: Геос, 2013.

Ames B. N., Durston W. E., Yamasaki E., Lee F. D. Carcinogens are Mutagens: A Simple Test System Combining Liver Homogenates for Activation and Bacteria for Detection // Proceedings of the National Academy of Sciences, 1973, 70 (8), 2281–2285.

Bartel D. P., Unrau P. J. Constructing an RNA world // Trends in Cell Biology, 1999, 9 (12), M9 — M13.

BiЕmont C., Vieira C. Genetics: junk DNA as an evolutionary force // Nature, 2006, 443 (7111), 521–524.

Couzin-Frankel J. Biomedicine. The bad luck of cancer // Science, 2015, 347 (6217):12.

Petrucelli N., Daly M. B., Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998, Sep 4 [updated 2016 Dec 15]. In: Adam M. P., Ardinger H. H., Pagon R. A., Wallace S. E., Bean L. J. H., Stephens K., Amemiya A., editors. SourceGeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 1993–2018.

zur Hausen H. Viruses in human cancers // Science, 1991, Nov 22; 254 (5035), 1167–1173.

Shih C., Padhy L. C., Murray M., Weinberg R. A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts // Nature, 1981, 90 (5803), 261–264.

Smithers D. W. Family Histories of 459 Patients with Cancer of the Breast // The British Journal of Cancer, 1948, 2 (2), 163–167.

Van Gent D. C., Kanaar R. Exploiting DNA repair defects for novel cancer therapies. Molecular and Cellular Biology, 2016, 27 (14), 2145–2148.

Vogelstein B., Kinzler K. W. Cancer genes and the pathways they control // Nature Medicine, 2004, 10 (8), 789–799.

Weinberg C. R., Zaykin D. J. Is bad luck the main cause of cancer? // Journal of the National Cancer Institute, 2015, 107 (7).

Yoshida K., Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Science, 2004, 95 (11), 866–871.

Глава 3. Секреты клеточного деления и мифы о химиотерапии

Зинченко В. П., Долгачева Л. П. Внутриклеточная сигнализация. — Пущино: Аналитическая микроскопия, 2003. (Электронная версия учебного пособия.)

Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug // Nature Reviews Drug Discovery, 2002, Jul; 1 (7), 493–502. Chen R., Shi L., Hakenberg J., Naughton B., Sklar P., Zhang J., Zhou H., Tian L., Prakash O., Lemire M., Sleiman P., Cheng W. Y., Chen W., Shah H., Shen Y., Fromer M., Omberg L., Deardorff M. A., Zackai E., Bobe J. R., Levin E., Hudson T. J., Groop L., Wang J., Hakonarson H., Wojcicki A., Diaz G. A., Edelmann L., Schadt E. E., Friend S. H. Analysis of 589, 306 genomes identifies individuals resilient to severe Mendelian childhood diseases // Nature Biotechnology, 2016, 34 (5), 531–538.

Cytotoxic Chemotherapy Mechanisms of Action. https://www.mycancergenome.org/content/molecular-medicine/pathways/cytotoxic-chemotherapy-mechanisms-of-action.

DeVita V. T. Jr, Chu E. A history of cancer chemotherapy. Cancer Research, 2008, 68 (21), 8643–8653.

Jordan V. C. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer // Endocrine-Related Cancer, 2014, 21 (3), 235–246.

Nowell P. C. The clonal evolution of tumor cell populations // Science, 1976, 194 (4260), 23–28.

Vogelstein B., Kinzler K. W. Cancer genes and the pathways they control // Nature Medicine, 2004, 10 (8), 789–799.

Vu T., Claret F. X. Trastuzumab: updated mechanisms of action and resistance in breast cancer // Frontiers in Oncology, 2012, 2, 62.

White J. Secret superheroes // New Scientist, 223 (2979), 28–29.

Глава 4. История HeLa и мифы о смерти и бессмертии

Склут Р. Бессмертная жизнь Генриетты Лакс. — М.: Карьера Пресс, 2012.

Abegglen L. M., Caulin A. F., Chan A., Lee K., Robinson R., Campbell M. S., Kiso W. K., Schmitt D. L., Waddell P. J., Bhaskara S., Jensen S. T., Maley C. C., Schiffman J. D. Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans // The Journal of the American Medical Association, 2015, 314 (17), 1850–1860.

Dawson M. A., Kouzarides T. Cancer epigenetics: from mechanism to therapy // Cell, 2012, 150 (1), 12–27.

Flynn R. L., Cox K. E., Jeitany M., Wakimoto H., Bryll A. R., Ganem N. J., Bersani F., Pineda J. R., Suvà M. L., Benes C. H., Haber D. A., Boussin F. D., Zou L. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors // Science, 2015, 347 (6219), 273–277.

Hao X., Luo H., Krawczyk M., Wei W., Wang W., Wang J., Flagg K., Hou J., Zhang H., Yi S., Jafari M., Lin D., Chung C., Caughey B. A., Li G., Dhar D., Shi W., Zheng L., Hou R., Zhu J., Zhao L., Fu X., Zhang E., Zhang C., Zhu J. K., Karin M., Xu R. H., Zhang K. DNA methylation markers for diagnosis and prognosis of common cancers // Proceedings of the National Academy of Sciences, 2017, 114 (28), 7414–7419.